,25 A recent clinical trial of infigratinib in patients with recurrent/progressive glioma and any FGFR alteration revealed durable disease control lasting >1 year in patients with FGFR1/3 point mutations or FGFR3-TACC3 fusions.47 This evidence concerns the gene TACC3 and glioma.